|
ABOUT VENTURE INTO CURES: THE LIVE EVENT IN NEW YORK
Join us for EB Research Partnership's 13th Annual Benefit on Thursday, November 10th, 2022 at 583 Park Avenue in New York, NY. The event will raise awareness and funds for critical research to treat and cure Epidermolysis Bullosa (EB), a life-threatening genetic disorder that affects children from birth. More details will be announced soon!
To purchase tickets or a sponsorship, click the button below and for additional sponsorship information, please reach out to Maxson Thomas at maxson@ebresearch.org. More details |
For the past two years, Venture Into Cures has shared inspirational stories of EB families alongside celebrity friends including Jill & Eddie Vedder, Tom Holland, Selena Gomez, and many more. Combined, the 2020 and 2021 shows have raised nearly $5M for critical EB research, and has been seen by millions of people worldwide.
This free, family-friendly, one-hour digital show will be broadcast on Sunday, November 20th, 2022.
Details on how to watch this year's show will be released soon. If you'd like to sponsor the digital show, or inquire about packages for both the in-person event and digital show combined, please email Maxson Thomas at maxson@ebresearch.org.
This free, family-friendly, one-hour digital show will be broadcast on Sunday, November 20th, 2022.
Details on how to watch this year's show will be released soon. If you'd like to sponsor the digital show, or inquire about packages for both the in-person event and digital show combined, please email Maxson Thomas at maxson@ebresearch.org.
|
ABOUT EB RESEARCH PARTNERSHIP
Epidermolysis Bullosa Research Partnership (EBRP) was founded in 2010 by Jamie and Alex Silver along with Jill and Eddie Vedder (Pearl Jam) with one bold audacious goal: treat and cure the devastating and life-threatening genetic rare skin disease epidermolysis bullosa and in the process pioneer an innovative business and technology model to lead the way for 400 million people with a are disease. As EB is typically caused by a single genetic mutation and treatments are observable on the surface of the skin, EB is first off the runway for impactful and curative medicine such as gene, stem cell, and immune therapies. Leading researchers believe a meaningful treatment or a cure is achievable before the end of this decade. While EB is a rare disease, there are 7,000 rare diseases that affect 1 in 10 people in the world, 95% which have no treatments, that can benefit from the research EBRP funds and its innovative venture philanthropy model - both of which are scalable to all rare diseases. To learn more, visit ebresearch.org |
|
